Alzheimer's disease (AD) is the most common chronic neurodegenerative disease today, afflicting 35 million people worldwide. Age is the major risk factor. The heritability of AD is estimated to be around 60%. Less than 5% of AD cases are familial with early-onset of disease caused by specific gene mutations. Genetic studies over the past 2 decades have provided invaluable insights into this complex disease. Here we review AD from the latest genome-wide association studies (GWAS), and a brief review of the transcriptomics, proteomics, metabolomics and epigenetics. Ultimately, a system-wide approach is essential to integrating the diverse and complicated findings into a meaningful understanding of AD.
INtrODUctION
Alzheimer's disease (AD) is a major public health issue, afflicting 35 million people worldwide. It has become the most prevalent neurodegenerative disease today. The diagnosis of AD is made based on clinical assessment and can only be confirmed post-mortem. A widely-used diagnostic criterion is that of the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) 1 . For possible or probable AD, the criteria are cognitive impairment, a suspected dementia syndrome determined by clinical examination and documented by neuropsychological testing. Post-mortem histological features are neuritic plaques comprising extracellular aggregates of amyloid beta (Aβ) protein in the brain parenchyma and blood vessel walls; and neurofibrillary tangles which have distinctive paired helical structures 4 . The main component of the neurofibrillary tangles is tau, a highly soluble microtubule-associated protein. Its function is to stabilise microtubules, specifically in axons, in a phosphorylation-dependent manner. There is significant associated neuronal loss in the frontal cortex and hippocampal regions. Currently the diagnosis of AD is by clinical assessment, however specificity and sensitivity of clinical diagnosis has been estimated to be 0.93 and 0.55 3, 4 . Neuropsychological testing and neuroimaging increase diagnostic precision in clinical diagnosis.
Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 spectrum of AD The level of cognitive impairment in AD ranges from age-appropriate cognitive decline, to mild cognitive impairment (MCI) and finally to dementia. AD is broadly classified into 2 subtypes:
1 Early onset familial AD (EOFAD) which is rare, presenting with an early onset and follows autosomal dominant transmission.
2 Late onset AD (LOAD), a more common, sporadic form that usually occurs later in life.
The 2 forms are differentiated by familial clustering and age of onset, but are not distinguishable clinically or histopathologically. However, most cases of AD with onset prior to age 65 are earlier manifestations of LOAD rather than EOFAD.
Over the recent years, an intermediate stage known as mild cognitive impairment (MCI), has garnered much clinical and research significance. It refers to non-demented persons with cognitive deficits, and represents a clinical syndrome that has been shown to have a high risk of progressing to dementias including AD 5 . A working definition by Petersen describes individuals with memory impairment greater than expected for their age but otherwise function independently and do not meet criteria for dementia 6 . In a large meta-analysis, the annual conversion from MCI to AD was reported as 6.5% (95% confidence interval = 4.8-8.5%) 7 . MCI will be a crucial stage when disease-modifying treatments for AD become available in future.
GENEtIcs OF AD
The heritability of AD is estimated to be around 60%. A recent study based on the Swedish Twin Registry reported the concordance rates for AD as 59% for monozygotic twins, 32% for like-sexed, and 24% for unlike-sexed dizygotic twins 8 . Environmental factors like lifestyle, medical co-morbidities, trauma etc. may make up the remaining risks.
Early-onset Familial AD
EOFAD which follows a Mendelian autosomal dominant inheritance makes up less than 5% of all AD. Three genes have been identified for which multiple mutations can lead to AD and have helped to boost understanding of AD pathology. These genes are the β-amyloid precursor protein (APP) gene on chromosome 21q, the presenilin 1 (PSEN1) gene on 14q, and presenilin 2 (PSEN2) gene on 1q.
These mutations affect Amyloid Precursor Protein (APP) processing and result in the increased synthesis of Aβ40 and Aβ42. Amyloid plaques are formed from the aggregation of these peptides. Down Syndrome patients with Trisomy 21 have been established to have a much higher risk of early-onset AD than usual. This is causally related to the over-expression and increased processing of β-APP, leading inexorably to early formation of plaques and subsequent AD 9 .
The sequence of transition from old age to MCI to AD has been found to be temporally related to the total tau burden of tau deposition 10, 11 .
Late Onset AD Apolipoprotein e4 (APOE e4) has been shown by association studies to be a genetic susceptibility factor, and another allele e2 to be likely protective. Apolipoprotein has three alleles e2, e3, e4 located on chromosome 19. They encode cholesterol transport protein APOE, the primary cholesterol transporter in the brain. They are important in the regulation of cholesterol and triglyceride metabolism. They are also present in amyloid plaques. The mechanism for the damaging effects of APOE isoforms remains unclear. Some studies suggest that APOE e4 is a disease modifier exerting its effect on disease risk by influencing age of onset rather than disease risk per se 12 .
In 25% of LOAD patients, there is at least 1 affected relative in the family 13 . In Caucasian populations, a 3-fold increased risk of developing AD has been reported for heterozygous APOE e4 and 8-fold risk in homozygous APOE e4 14 . However half of the people who develop AD do not carry the APOE e4 allele 15 .
Genome-wide Association studies (GWAs)
Compared to traditional hypothesis-driven genetic studies, Genome-wide Association Studies (GWAS) look at genetic variation across an entire genome. This follows advancements in microarray platforms that allow us to survey the human genome for single base pair differences -single-nucleotide polymorphisms (SNPs) -across many disease cases and unaffected controls.
Grupe et al in 2007 performed the first GWAS on AD. They found that only SNPs proximally located to the APOE gene were strongly associated with AD 15 . A second study in over 1,000 individual unrelated AD cases and control subjects also demonstrated that only the APOE e4 allele was strongly linked to AD 17 .
GRB2-associated binding protein 2 (GAB2) was found to be strongly associated with APOE e4 in AD patients [18] [19] [20] . GAB2 is an adaptor protein that recruits signalling modules in the cell. It could modulate the activities of certain kinases to facilitate the formation of amyloid plaques and neurofibrillary tangles 21 .
Thirty-six SNPs were shown to be strongly associated with LOAD in a Japanese population. These included APOE, apoprotein C1 (APOC1), translocase of outer mitochondrial membrane 40 (TOMM40) and poliovirus receptor-related 2 (PVRL2) 22 . APOC1 is involved in lipoprotein and lipid metabolism 23 . PVRL2 has been previously reported to be associated with AD and is the entry mediator for herpes simplex virus type 1 (HSV-1) 24 . HSV-1 may play a role in tranducing an environmental pathogen 25, 26 . TOMM40 has been shown to be associated to LOAD in other studies 27, 28, 29 . In a GWAS using hippocampal atrophy as an additional neuroimaging-based quantitative phenotype, TOMM40 was found in AD subjects twice as frequently as in controls 27 . TOMM40 is found in mitochodria and mutations may be linked to increased oxidative stress and degeneration 24, 30 .
These may point to the possibility of mitochondrialbased therapies for treating AD.
Other genes have been found in association with LOAD but with inconsistent replication. These include ubiquilin 1 (UBQLN1), a presenilin interactor that promotes the accumulation of presenilin 1 protein and regulates its endoproteolysis 31 ; insulin degrading enzyme (IDE), which regulates Aβ42 levels in brain neurons and microglial cells 32, 33 ; sortilin-related sorting receptor (SORL1). Under-expression of SORL1 leads to APP released into late endosomal pathways and processed by beta-secretase cleavage and yielding Aβ 34, 35 . SORL1 may also possibly affect LOAD through a female -specific mechanism in a casecontrol study 36 .
Another recent GWAS on more than 35,000 persons confirmed 2 putative candidate genes clusterin (CLU) and phosphatidylinositol-binding clathrin assembly protein (PICALM) to be associated with AD. This study additionally found 2 novel genetic loci to be implicated as well: rs744373 near BIN1 and rs597668 near EXOC3L2/BLOC1S3/MARK4 37 .
Interestingly, the search for protective genes has yielded positive results as well. Polymorphisms of the cholesterol ester transfer protein (CETP) gene have been associated with longevity, slower rates of memory decline and lower incidence of dementia 38 brain sampling. Conversely, studying individual cells or cell types ignores its complex nature. We can also study transgenic mice or cell lines. A combination of approaches will likely yield more meaningful results.
transcriptomics or Genome-wide Expression Profiling
Genome-wide gene expression profiling, or transcriptomics looks at which genes are actually transcribed into messenger RNA (mRNA). An individual has 1 genome but multiple transcriptomes. The transcriptome varies depending on tissue types, time, internal or external milieu, epigenetic influences or pre-programmed changes. Significant differences in mRNA levels implies that the genes are expressed to different degrees, probably leading to different levels of protein translation. Transcriptomics employs high-throughput techniques based on DNA microarray technology. Analysis entails sophisticated statistical methods to reduce the false positive and the false discovery rates. Multiple studies are compared for replication of findings. We need to know if the findings from transcriptomics correspond to those obtained from classical genetics or GWAS.
The genome-transcriptome link was demonstrated by Liang et al in a comparison of AD brains with that of healthy controls 41 . They showed that different regions of the brain have distinct expression profiles by analysing 6 discrete postmortem brain regions -entorhinal cortex, hippocampus, medial temporal, posterior cingulate, superior frontal gyri and primary visual cortex. There was significant correlation between their findings with results obtained by genotyping and GWAS.
Tan et al further showed that there were consistent patterns of change in the gene expression profile in the neocortex of AD subjects 42 . The AD transcriptome indicated evidence of synaptic dysfunction, disturbed neurotransmission and activation of neuroinflammation.
Gene expression profiling of peripheral blood has been shown to provide distinctive profiles for different neurological conditions 43, 44 . Subjects with psychiatric disorders were also found to have unique gene-expression signatures in their blood compared to normal controls 45 .
Proteomics
Proteomics is the study of both the structure and function of proteins across the whole organism 18 . The complete protein complement of a cell is referred to as the proteome. Advancing technologies, especially the evolution of 2D gel electrophoresis-based approaches into liquid chromatography-based high resolution tandem mass spectrometry have dramatically improved the speed and precision of identification and measurement of proteins in biological fluids. Like transcriptomics, proteomics is usually applied to compare the differences in abundances of proteins between diseased and normal subjects. The proteomic techniques have been applied to discover biomarkers for AD in CSF.
German et al reported finding 3 discriminating peaks in common but they still await identification of the protein and peptides 46 . Portelius proposed that targeted proteomics on Aβ may provide novel assays for biomarkers for AD 47 . Thambisetty et al, using a combined proteomic and neuroimaging approach, reported that clusterin/apolipoprotein J was associated with atrophy of the entorhinal cortex, baseline disease severity and rapid clinical progression in AD 48 .
Metabolomics
Metabolomics is the study of the regulation of metabolic pathways and metabolic networks 49 . These involve small-molecule metabolites, such as metabolic intermediates, hormones, signalling molecules, and secondary metabolites. Metabolomic profiling is the quantitative measurement of these metabolites within a particular sample type 50 . The metabolome captures the status of diverse biochemical pathways at a particular moment and defines a metabolic state such as health or disease state. The metabolome is dynamic, changing from minute to minute. It is not currently possible to analyse the entire range of metabolites by a single analytical method.
In the search for AD biomarkers, analysis of the protein fraction of both blood plasma and CSF has been used extensively. Ideal biomarkers should be easy and inexpensive to assay, with high specificity and sensitivity, and be able to quantify disease state and progression. Nicola et al investigated novel biomarkers and found that certain bile acids were upregulated in MCI and AD 51 usefulness of the findings await further replication and interpretation.
Epigenomics
Epigenetics refers to molecular and cellular effects on gene expression without a change in the DNA sequence. These include DNA methylation, histone modification and RNA mediated gene silencing. Epigenomics is the genomic-wide study of epigenetic effects. All nucleated cells in an individual may contain different epigenomes depending on tissue type, developmental stage, age and other parameters 52, 53 . These can be transmitted into the next generation without a change in the underlying DNA code. Epigenetic contribution is vital to achieve either stable expression or repression of genes at various stages of development 54 .
Epigenetic contribution in the development of LOAD could be inferred from several findings according to Wang et al 55 . Sporadic cases dominate over familial ones; concordance rate of monozygotic twins are well below 100%; differential susceptibility and course of illness in males and females; parent-of-origin effect; and relatively late age of onset of disease. They also found evidence which indicated abnormal methylation homeostasis and epigenetic dysregulation. The difference in penetrance and expressivity can be attributed in part to epigenetic phenomenon, even in cases of EOFAD. The epigenome may be susceptible to deregulation during embryonic and neonatal development, puberty and old age. There were substantial differences in the epigenetic profiles between old monozygotic twins that can be attributed to one's environment. Neuronal tissue in the AD brain may be prone to collecting epimutations with time due to their post-mitotic state, as opposed to cells which are constantly being renewed.
Wu et al found that early exposure to xenobiotic lead in rodents increases APP and Abeta production later in the ageing brain, as well as the oxidative DNA marker 8-oxo-dG. This suggests that early life environmental experiences may contribute to late life amyloidogenesis via epigenetics 55 .
sYstEMs bIOLOGY: bLIND MEN AND AN ELEPHANt
Systems biology refers to an integrative analysis of interacting biological pathways in which multiple structurally and functionally diverse biomolecules are measured simultaneously across time, space, within cells, tissues or the whole organism. Past genetic studies often focused on 1 aspect and ignored the complexity of each disease, analogous to the old adage of many blind men each exploring one part of an elephant. The challenge is how to transform these findings from the above platforms into a meaningful biological pathophysiology, to be able to understand a complete picture of the elephant. Gene interaction networks using powerful computational tools and bioinformatics are being developed to make this possible 57 .
Complex gene-environment interactions need to be understood in the context of other findings as well. An illustration of a gene-environment interaction was shown by Sun et al who found a functional hypoxia-responsive element in the BACE1 gene promoter. Hypoxia facilitated upregulation of BACE1 gene expression and increased Aβ deposition and memory deficits in APP transgenic mice, and hence a plausible mechanism linking vascular factors and stroke with the development of AD 57 .
APPLIcAtION OF GENOMIcs
Genomics have also been useful in the development of biomarkers for diagnosis and monitoring the progress of AD and the response of treatment. Other important applications involve pharmacogenetics and the discovery of new treatments.
biomarkers
The race is on to find objective markers derived from blood and CSF which are more economical and can be re-sampled. Some promising markers include phosphorylated tau protein. It is found to be increased in CSF in AD patients with specificity and sensitivity of around 90%. Aβ peptide in plasma and other substances in blood investigated have not had the requisite sensitivity and specificity 58, 59 .
the Next Frontier: Drug Discovery
The use of genomic information has led to a new paradigm shift in drug discovery and development especially in complex diseases like AD. Pharmacogenomics is the study of interindividual genetic variability which plays a significant role in predicting drug response and toxicity 63 . Then we can individualise the best possible treatment option. Donepezil is metabolised via Cytochrome (CYP)related enzymes. Cacabelos estimated that 15-20% of AD patients may exhibit abnormal metabolism of anticholinesterases 60 . About half of these may be ultrarapid metabolisers, requiring higher doses of drug to reach a therapeutic threshold, whereas the other half are poor metabolisers and have adverse effects even at low doses. APOE genotypes may affect the degree of drug responsiveness in AD patients treated with cholinesterase inhibitors 61, 62 . Another prospective study using donepezil in AD subjects found that those with a G allele of the CYP 2D6 gene had significantly reduced response compared to those without 63 .
Symptomatic medications like cholinesterase inhibitors and one NMDA receptor antagonist, memantine are approved for use in AD currently. However, they are not disease modifying, and the treatment effects remain variable. Disease modifying agents that can retard, arrest or even reverse the pathophysiological processes are urgently needed. Drugs are targeting the reduction of amyloid deposits, tau phosphorylation or a combination approach. Many of the pathways described have been yet to be proven targets for therapy.
It is a challenge to discover drugs that penetrate the blood-brain barrier well yet remain safe physiologically. Much attention has been focused on gamma and beta secretases, BACE and SORL1 that would lead to decreasing Aβ production or its accumulation 11 . Gamma-secretase inhibitors may unfortunately cause toxicities associated with proteolysis of other substrates, e.g. the Notch receptor proteins 64, 65 . Valproic acid decreased Aβ production by inhibiting GSK-3β-mediated γ-secretase cleavage of APP in a mouse model 66 .
Bepridil and amiodarone which are calcium channel blockers were found to target beta and gamma secretases simultaneously in guinea pigs 67 .
Other drug targets involve tau phosphorylation, mitochondrial dysfunction, failure of molecular transport mechanisms, oxidative damage, inflammation and cell cycle dysregulation 68 . An inhibitor of tau protein aggregation is methylthioninium chloride with the trade-name Rember™. Pioglitazone, a drug used in diabetes, appeared to have effects on the peripheral and central markers of ageing in rats 69 . Another exciting possibility is Abeta immunotherapy. Both active and passive immunisation have been shown to lower cerebral Abeta levels and improve cognition in animal models. A clinical trial was stopped in the phase II stage when about 6% of immunised patients developed meningoencephalitis, however some plaque clearance and clinical improvements were observed post-immunisation. Extrapolating from this, many passive and active vaccines are now being conducted in various test sites 70 . Histone deacetylase-2 (HDAC2) were found to enhance memory and synaptic function in hippocampal areas in transgenic mice, and happen to be inhibited by valproic acid 71 .
sUMMArY High throughput technologies have led to a better understanding of AD, although the impact for clinical practice remains limited currently. It is evident that LOAD is not caused by the presence of one or a few genes but a complex interaction of multiple genes, their transcription, translation, and environmental inputs. A systems approach to integrating the diversity of findings from these technologies is necessary. Psychogenomics will help push the development of new drugs. Early diagnosis and intervention will become crucial given the prospect of disease modifying drugs in the near horizon.
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